- Home
- AIM vs CDT Comparison
AIM vs CDT Comparison
Compare AIM & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIM
- CDT
- Stock Information
- Founded
- AIM 1966
- CDT 2019
- Country
- AIM United States
- CDT United States
- Employees
- AIM N/A
- CDT N/A
- Industry
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- AIM Health Care
- CDT Health Care
- Exchange
- AIM Nasdaq
- CDT Nasdaq
- Market Cap
- AIM 9.8M
- CDT 11.1M
- IPO Year
- AIM N/A
- CDT N/A
- Fundamental
- Price
- AIM $0.14
- CDT $1.15
- Analyst Decision
- AIM Strong Buy
- CDT
- Analyst Count
- AIM 2
- CDT 0
- Target Price
- AIM $2.75
- CDT N/A
- AVG Volume (30 Days)
- AIM 1.5M
- CDT 8.8M
- Earning Date
- AIM 04-01-2025
- CDT 03-04-2025
- Dividend Yield
- AIM N/A
- CDT N/A
- EPS Growth
- AIM N/A
- CDT N/A
- EPS
- AIM N/A
- CDT N/A
- Revenue
- AIM $190,000.00
- CDT N/A
- Revenue This Year
- AIM N/A
- CDT N/A
- Revenue Next Year
- AIM $1,693.10
- CDT N/A
- P/E Ratio
- AIM N/A
- CDT N/A
- Revenue Growth
- AIM N/A
- CDT N/A
- 52 Week Low
- AIM $0.12
- CDT $1.13
- 52 Week High
- AIM $0.62
- CDT $392.00
- Technical
- Relative Strength Index (RSI)
- AIM 36.62
- CDT 31.53
- Support Level
- AIM $0.12
- CDT $1.60
- Resistance Level
- AIM $0.21
- CDT $3.70
- Average True Range (ATR)
- AIM 0.02
- CDT 0.44
- MACD
- AIM -0.00
- CDT 0.09
- Stochastic Oscillator
- AIM 22.88
- CDT 0.78
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.